Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Advanced Refractory Colorectal Cancer
NCT01929616Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Aug 2013
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in colorectal adenocarcinoma, sponsored by Institut Jules Bordet. Primary endpoint: Overall Survival at 2 years. Started Aug 2013; status: completed.
02
Drugs
regorafenib
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT01929616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01929616.